Onyx Healthcare (6569) reported revenue of NT$82.9 million for Oct 2026, -9.5% year on year and -31.9% from the previous month. Revenue for Jan–Oct 2026 was NT$1.2 billion (+10.3% year on year).
In Oct 2026, it ranked No. 85 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$82.9 million | -9.5% | -31.9% |
| Sep 2026 | NT$121.8 million | -2.1% | -9.9% |
| Aug 2026 | NT$135.3 million | +43.2% | +146.1% |
| Jul 2026 | NT$55 million | -50.6% | -65.9% |
| Jun 2026 | NT$161.2 million | +17.0% | -5.9% |
| May 2026 | NT$171.4 million | +49.8% | +77.4% |
| Apr 2026 | NT$96.6 million | -8.3% | -50.3% |
| Mar 2026 | NT$194.3 million | +49.2% | +84.9% |
| Feb 2026 | NT$105.1 million | +7.7% | +34.6% |
| Jan 2026 | NT$78 million | -5.0% | -39.1% |
| Dec 2025 | NT$128.2 million | -24.1% | +33.6% |
| Nov 2025 | NT$95.9 million | -7.6% | +4.7% |
| Oct 2025 | NT$91.6 million | -16.6% | -26.4% |
| Sep 2025 | NT$124.5 million | +34.6% | +31.8% |
| Aug 2025 | NT$94.5 million | -6.4% | -15.0% |
| Jul 2025 | NT$111.2 million | +22.7% | -19.3% |
| Jun 2025 | NT$137.7 million | +19.5% | +20.4% |
| May 2025 | NT$114.4 million | +60.1% | +8.6% |
| Apr 2025 | NT$105.3 million | -6.5% | -19.1% |
| Mar 2025 | NT$130.2 million | +15.4% | +33.5% |
| Feb 2025 | NT$97.5 million | +11.0% | +18.7% |
| Jan 2025 | NT$82.2 million | +10.1% | -51.3% |
| Dec 2024 | NT$168.8 million | +8.5% | +62.5% |
| Nov 2024 | NT$103.9 million | +4.0% | -5.5% |
| Oct 2024 | NT$109.9 million | -38.7% | +18.8% |
Jan–Oct 2026 cumulative: NT$1.2 billion (+10.3% YoY)
Other Biotech & Medical companies
Compare with peers: Onyx Healthcare vs PEC / Onyx Healthcare vs Lotus Pharm / Onyx Healthcare vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16